Blanca Arribas-Arribas
Research Subjects
Blanca Arribas-Arribas has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Beatriz Fernández-Muñoz
Cellular Reprogramming and Production Unit, Andalusian Network for the Design and Translation of Advanced Therapies, 41092 Sevilla, Spain
2 shared publications - Gloria Carmona
Unidad de Producción y Reprogramación Celular de Sevilla (UPRC), Red Andaluza de diseño y traslación de Terapias Avanzadas (RAdytTA), Fundación Pública Andaluza Progreso y Salud M.P, Seville, Spain
2 shared publications - Ana Belen Garcia-Delgado
Unidad de Producción y Reprogramación Celular (UPRC), Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RAdytTA), Fundación Progreso y Salud, 41092 Sevilla, Spain
1 shared publication - Beatriz Guijarro-Albaladejo
Instituto de Biomedicina de Sevilla (IBIS), Servicio de Hematología, Hospital Universitario Virgen del Rocío and Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Sevilla, Sevilla, Spain
1 shared publication Belén Sierro-Martínez
Instituto de Biomedicina de Sevilla (IBIS), Servicio de Hematología, Hospital Universitario Virgen del Rocío and Consejo Superior de Investigaciones Científicas (CSIC), Universidad de Sevilla, Sevilla, Spain
1 shared publication- Estefanía García-Guerrero
Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain.
1 shared publication
Latest Publications
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 6866
New Optimized Academic Anti-BCMA CAR (CARTemis-1): How Does the Manufacturing Process Impact CAR-T Cell Features?
Disclosures. Reguera:AMGEN: Speakers Bureau; KITE: Speakers Bureau; BMS: Speakers Bureau; Janssen: Consultancy, Speakers Bureau. Einsele:Takeda: Honoraria, Othe
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 6866
Open AccessNew Optimized Academic Anti-BCMA CAR (CARTemis-1): How Does the Manufacturing Process Impact CAR-T Cell Features?
Disclosures. Reguera:AMGEN: Speakers Bureau; KITE: Speakers Bureau; BMS: Speakers Bureau; Janssen: Consultancy, Speakers Bureau. Einsele:Takeda: Honoraria, Othe
- Open Access
- 28 October 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 168, 115769
Nanostructured fibrin-agarose hydrogels loaded with allogeneic fibroblasts as bio-dressings for acute treatment of massive burns
- 28 October 2023
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 168, 115769
Open AccessNanostructured fibrin-agarose hydrogels loaded with allogeneic fibroblasts as bio-dressings for acute treatment of massive burns
- Open Access
Human Neural Stem Cells for Cell-Based Medicinal Products
Neural stem cells represent an attractive tool for the development of regenerative therapies and are being tested in clinical trials for several neurological disorders. Human neural stem cells can be isolated from the central nervous system or can be derived in vitro from pluripotent stem cells. Embryonic sources are ethically controversial and other sources are less well characterized and/or inefficient. Recently, isolation of NSC from the cerebrospinal fluid of patients with spina bifida and with intracerebroventricular hemorrhage has been reported. Direct reprogramming may become another alternative if genetic and phenotypic stability of the reprogrammed cells is ensured. Here, we discuss the advantages and disadvantages of available sources of neural stem cells for the production of cell-based therapies for clinical applications. We review available safety and efficacy clinical data and discuss scalability and quality control considerations for manufacturing clinical grade cell products for successful clinical application.
Open AccessHuman Neural Stem Cells for Cell-Based Medicinal Products
Neural stem cells represent an attractive tool for the development of regenerative therapies and are being tested in clinical trials for several neurological disorders. Human neural stem cells can be isolated from the central nervous system or can be derived in vitro from pluripotent stem cells. Embryonic sources are ethically controversial and other sources are less well characterized and/or inefficient. Recently, isolation of NSC from the cerebrospinal fluid of patients with spina bifida and with intracerebroventricular hemorrhage has been reported. Direct reprogramming may become another alternative if genetic and phenotypic stability of the reprogrammed cells is ensured. Here, we discuss the advantages and disadvantages of available sources of neural stem cells for the production of cell-based therapies for clinical applications. We review available safety and efficacy clinical data and discuss scalability and quality control considerations for manufacturing clinical grade cell products for successful clinical application.